CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.

[1]  Matthew J. Frigault,et al.  The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  S. Albelda,et al.  CAR T Cell Therapy for Solid Tumors. , 2017, Annual review of medicine.

[3]  C. Ramos,et al.  Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  N. Bartlett,et al.  Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[6]  R. Junghans,et al.  Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response , 2016, The Prostate.

[7]  S. Rosenberg,et al.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Defrancesco.  Juno's wild ride , 2016, Nature Biotechnology.

[9]  M. Sadelain,et al.  Biology and clinical application of CAR T cells for B cell malignancies , 2016, International Journal of Hematology.

[10]  G. Wertheim,et al.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.

[11]  M. Vemuri,et al.  CAR T Cell Therapy: A Game Changer in Cancer Treatment , 2016, Journal of immunology research.

[12]  P. Adusumilli,et al.  A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial. , 2016, Immunotherapy.

[13]  Franco Locatelli,et al.  Overcoming Challenges in CAR T-cell Product CGMP Release. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Q. Lu,et al.  Special Topic: Fighting Cancer with Armed T Cells Phase 1 Clinical Trial Demonstrated That Muc1 Positive Metastatic Seminal Vesicle Cancer Can Be Effectively Eradicated by Modified Anti-muc1 Chimeric Antigen Receptor Transduced T Cells , 2022 .

[15]  D. Kranz,et al.  Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. , 2016, Trends in pharmacological sciences.

[16]  Hao Liu,et al.  Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Curran,et al.  Chimeric antigen receptor T cells for cancer immunotherapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Katz,et al.  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases , 2015, Clinical Cancer Research.

[19]  Ton N. Schumacher,et al.  Adoptive cellular therapy: A race to the finish line , 2015, Science Translational Medicine.

[20]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[22]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[23]  C. Creighton,et al.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.

[24]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[25]  Sadik H. Kassim,et al.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.

[26]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[27]  S. Rosenberg,et al.  Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.

[28]  B. Levine,et al.  T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans , 2013, Cancer Immunology Research.

[29]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[31]  G. Coukos,et al.  A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer , 2012, Journal of Translational Medicine.

[32]  S. Rosenberg,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[33]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[34]  D. Gibbons,et al.  Clinical trials for stem cell therapies , 2011, BMC medicine.

[35]  C. Flowers,et al.  Novel agents for diffuse large B-cell lymphoma , 2011, Expert opinion on investigational drugs.

[36]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[37]  F. Marincola,et al.  Melanoma‐associated antigen recognized by T cells (MART‐1) , 1999, Cancer.

[38]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Quan-shun Wang,et al.  Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.